查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1539234

製藥和生物技術產業藥物發現階段的合作條件和合約（2019-2024）

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024
出版日期: | 出版商: Current Partnering | 英文 2500+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告詳細了解並分析了公司如何、為何以及在什麼條件下進行藥物發現合作。這些交易屬於發現階段交易，其中被授權人獲得授權授權人的產品或技術的權利或選擇權。這些交易往往是跨部門的，從合作研發開始，一直延伸到成果的商業化。

本報告提供了醫學領域宣布的最新藥物發現協議的詳細資訊。

了解潛在合作夥伴談判的交易條款的靈活性有助於深入了解談判過程，了解條款談判期間的預期結果。雖然許多小型企業想要詳細的付款條款，但付款方式的問題在於細節。合約文件提供了新聞稿或資料庫中沒有的見解。

本報告包含自2019年以來宣布的所有藥物發現階段合作的完整列表，並包括交易各方披露的實際藥物發現合作的線上交易記錄，還包括超過 3,900個鏈接。此外，如果有的話，會記錄公司及其附屬公司向美國證券交易委員會提交的合約文件。

本報告包括數百家生命科學公司宣布的交易，包括Takeda、AstraZeneca、Eli Lilly、Sanofi、Boehringer Ingelheim、Merck、Roche、Bristol-Myers Squibb、Astellas、Twist Bioscienc等主要製藥公司。

本報告還包含大量圖表和圖表，顯示自2019年以來藥物發現階段的合作夥伴關係和交易相關的趨勢和活動。

此外，還提供了自2019年以來所有發現的綜合附錄，按合作夥伴名稱（A-Z）、病例類型、治療重點領域和技術類型進行組織。每筆交易的標題都透過網路連結連結到交易記錄的線上版本，並在可用的情況下連結到合約文件，以便在需要時輕鬆存取每個合約文件。

總而言之，本報告提供了潛在交易者需要了解的有關發現階段產品和化合物的研究、開發和商業化合作的所有資訊。

主要優點

本報告為讀者提供了以下主要優點：

  • 有關藥物發現階段合約趨勢的詳細資訊（自2019年起）
  • 存取交易總額、預付款、里程碑和忠誠度資料
  • 利用大量真實案例研究分析藥物發現階段的合約結構
  • 實踐中的條款範例以及對藥物發現階段合約中包含的條款的深入了解
  • 公司在過往交易中商定的主要交易條款的識別
  • 進行實質審查：評估向合作夥伴公司提出的合約條款的適用性

調查範圍

  • 本報告目的是讓讀者深入了解和了解全球領先公司簽訂的藥物發現階段協議的趨勢和結構。

本報告提供的資訊：

  • 生物製藥產業藥物發現階段的交易趨勢（2019年起）
  • 藥物發現階段的交易結構分析
  • 存取交易總額、預付款、里程碑和忠誠度資料
  • 實際藥物發現階段計畫的案例研究
  • 參與藥物發現階段的案件（超過 2,900個）
  • 藥物發現階段的主要案件（依據金額，2019年起）
  • 藥物發現階段最活躍的交易撮合者（2019年起）
  • 藥物發現階段的主要聯盟（2019）

此報告列出了可用合約的以下資訊：

  • 公司名稱（A-Z）
  • 總交易金額
  • 合約簽訂時的開發階段
  • 合約類型
  • 具體治療標靶
  • 每筆交易的標題都透過網路連結連結到交易記錄的線上版本以及合約文件（如果有），可以輕鬆按需存取每份合約文件。

此報告提供了對 2,900 多個藥物發現階段交易的可用交易和合約文件的全面存取。分析實際合約協議能夠評估：

  • 授予或選擇的具體權利是什麼？
  • 合約實際上賦予了合作夥伴公司什麼？
  • 授予哪些類型的專有權？
  • 合約的付款結構是怎樣的？
  • 如何審核銷售和付款？
  • 條款和條件是什麼？
  • 合約的主要條款是如何定義的？
  • 智慧財產權的處理和所有權如何？
  • 誰負責商業化？
  • 誰負責開發、供應和製造？
  • 如何管理保密和發布？
  • 如何解決爭議？
  • 什麼情況下可以取消合約？
  • 如果所有者發生變化會怎樣？
  • 已就何種類型的再授權或分包契約達成協議？
  • 公司主張哪些樣板條款？
  • 根據合作夥伴關係或交易的類型，哪些樣板條款看起來有所不同？
  • 公司對契約法主張哪一個管轄權？

目錄

執行摘要

第1章 簡介

第2章 公司在藥物發現階段合作的原因

  • 簡介
  • 夥伴關係在藥物發現階段的作用
    • 藥物發現階段的許可引進
    • 藥物發現階段的許可
  • 藥物發現、臨床前和臨床階段交易的差異
  • 在藥物發現階段簽訂合作協議的原因
    • 為什麼許可方（許可方）在藥物發現階段簽訂合約
    • 為什麼被許可人（被許可人）在藥物發現階段簽訂合約
  • 藥物發現階段協作交易的未來

第3章 藥物發現階段的交易策略與結構

  • 簡介
  • 公司在什麼階段結盟？
    • 製藥/生技領域的早期合作
    • 製藥/生技領域的後期合作
  • 早期與後期聯盟：比較風險/成本
  • 公司在藥物發現、臨床前和臨床階段花了多少錢？
  • 純/複合組件合作協議
  • 純粹授權協議的結構
    • 純許可協議範例
    • a.個案研究（9）
    • b.個案研究（10）
  • 複雜成分和藥物發現階段的合作協議
    • a. 多個組成部分/開頭子句的範例
    • a.個案研究（11）
    • b.個案研究（12）

第4章 藥物發現階段合作的支付策略

  • 簡介
  • 藥物發現階段的支付策略
  • 付款方式
    • 總交易金額
    • 預付款
    • 貸款
    • 可轉換貸款
    • 股權
    • 研發資金
    • 許可費
    • 里程碑付款
    • 特許權使用費
    • QUIDS
    • Option payments

第5章 藥物發現階段的交易趨勢

  • 簡介
  • 近期在藥物發現階段的合作
    • 藥物發現交易的屬性
  • 藥物發現階段的合作關係：依交易類型劃分
  • 藥物發現階段的合作關係：依疾病類型劃分
  • 藥物發現階段的合作：依技術類型
  • 與最活躍的公司在藥物發現階段建立合作關係（2019-2024年）

第6章 藥物發現階段合作的付款條件

  • 簡介
  • 有關藥物發現階段付款條件的指南
    • 預付款
    • 里程碑付款
    • 特許權使用費
  • 藥物發現階段的支付條件：交易資料分析
    • 公開資料
    • 調查資料
  • 付款條件分析
    • 藥物發現階段的交易總額
    • 藥物發現階段的交易：預付款
    • 藥物發現階段交易：里程碑付款
    • 藥物發現階段的特許權使用費

第7章 藥物發現階段的重大交易

  • 簡介
  • 藥物發現階段的主要交易：依交易金額

第8章 藥物發現階段的交易撮合者：前 25 家公司

  • 簡介
  • 最活躍的藥物發現階段交易撮合者：前 25 名公司

第9章 藥物發現階段合作協議清單

  • 簡介
  • 藥物發現階段的合約交易（2019-2024）

第10章 藥物發現階段的交易：依開發階段劃分

  • 簡介
  • 依藥物發現階段劃分的交易

附錄

簡介目錄
Product Code: CP2056

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest discovery agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2019 including financial terms where available including over 3,900 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2019. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.

Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 25 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2019, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2019.

The report includes deals announced by hundreds of life science companies including big pharma such as Takeda, AstraZeneca, Eli Lilly, Sanofi, Boehringer Ingelheim, Merck, Roche, Bristol-Myers Squibb, Astellas, Twist Bioscience and many more.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2019.

In addition, a comprehensive appendix of all discovery deals since 2019 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Key benefits

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 provide the reader with the following key benefits:

  • In-depth understanding of discovery stage deal trends since 2019
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Insight into the terms included in a discovery stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 include:

  • Trends in discovery stage dealmaking in the biopharma industry since 2019
  • Analysis of discovery stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life discovery stage deals
  • Access to over 2,900 discovery stage deals
  • The leading discovery stage deals by value since 2019
  • Most active discovery stage dealmakers since 2019
  • The leading discovery stage partnering 2019

In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 report provides comprehensive access to available deals and contract documents for over 2,900 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

  • 2.1. Introduction
  • 2.2. The role of discovery stage partnering
    • 2.2.1. In-licensing at discovery stage
    • 2.2.2. Out-licensing at discovery stage
  • 2.3. Difference between discovery, preclinical and clinical stage deals
  • 2.4. Reasons for entering into discovery stage partnering deals
    • 2.4.1. Licensors reasons for entering discovery stage deals
    • 2.4.2. Licensees reasons for entering discovery stage deals
  • 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study 1
    • 3.2.1.1.b. Case study 2
    • 3.2.1.1.c. Case study 3
    • 3.2.1.1.d. Case study 4
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study 5
    • 3.2.2.1.b. Case study 6
    • 3.2.2.1.c. Case study 7
    • 3.2.2.1.d. Case study 8
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study 9
    • 3.6.1.b. Case study 10
  • 3.7. Multicomponent discovery stage partnering agreements
    • 3.7.1.a. Example multicomponent early stage clauses
    • 3.7.1.a. Case study 11
    • 3.7.1.b. Case study 12

Chapter 4 - Discovery stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Discovery stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study 13
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

  • 5.1. Introduction
  • 5.2. Discovery stage partnering over the years
    • 5.2.1. Attributes of discovery deals
  • 5.3. Discovery stage partnering by deal type
  • 5.4. Discovery stage partnering by disease type
  • 5.5. Partnering by discovery stage technology type
  • 5.6. Discovery stage partnering by most active company, 2019 to 2024

Chapter 6 - Payment terms for discovery stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for discovery stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Discovery stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Discovery stage headline values
    • 6.4.2. Discovery stage deal upfront payments
    • 6.4.3. Discovery stage deal milestone payments
    • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

  • 7.1. Introduction
  • 7.2. Top discovery stage deals by value

Chapter 8 - Top 25 most active discovery stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 25 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Discovery stage deals with contracts 2019 to 2024

Chapter 10 - Discovery stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by discovery stage

Appendices

  • Appendix 1 - Discovery stage dealmaking by companies A-Z
  • Appendix 2 - Discovery stage dealmaking by industry sector
  • Appendix 3 - Discovery stage dealmaking by stage of development
  • Appendix 4 - Discovery stage dealmaking by therapy area
  • Appendix 5 - Discovery stage dealmaking by technology type
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
  • Figure 3: Components of the pure licensing deal structure
  • Figure 4: Payment options for discovery stage partnering deals
  • Figure 5: Issues affecting royalty rates
  • Figure 6: Discovery stage partnering frequency 2019 - 2024
  • Figure 7: Discovery stage partnering by deal type since 2019
  • Figure 8: Discovery stage partnering by disease type since 2019
  • Figure 9: Discovery stage partnering by technology type since 2019
  • Figure 10: Top 25 most active discovery stage dealmakers, 2019 to 2024
  • Figure 11: Review of median upfront payments for discovery stage deals
  • Figure 12: Review of median milestone payments for discovery stage deals
  • Figure 13: Review of median royalty payments for discovery stage deals
  • Figure 14: Discovery stage deals with a headline value
  • Figure 15: Discovery stage deals with an upfront value
  • Figure 16: Discovery stage deals with a milestone value
  • Figure 17: Discovery stage deals with a royalty rate value
  • Figure 18: Top discovery stage deals by deal value since 2019
  • Figure 19: Most active discovery stage dealmakers 2019 to 2024